3 Earnings Reports That Caught My Attention Last Week
Among the carnage, there were a few bright spots, including two new drugs that may begin to make up for some of Lexapro's lost revenue. One, which I highlighted in December, is Linzess, an irritable bowel syndrome and constipation drug developed with …
Full News here – Read more on Motley Fool










